J. Scott Garland Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for J. Scott Garland.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of J. Scott Garland. J. Scott Garland is EVP & Chief Commerical Officer in EXELIXIS, INC. ($EXEL) and President and CEO in PORTOLA PHARMACEUTICALS INC ($PTLA) and SVP & Chief Commercial Officer in Relypsa Inc ($RLYP) and Director in Calithera Biosciences, Inc. ($CALA) and Director in Karyopharm Therapeutics Inc. ($KPTI).
Latest Insider Trading Transactions of J. Scott Garland
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, CALA, EXEL, KPTI, PTLA, RLYP
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 04 2020 | CALA | Calithera Bioscien ... | Garland J. Scott | Director | Option Exercise | A | 4.70 | 40,000 | 188,000 | 40,000 | |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | D | 0.00 | 153,399 | 0 | 0 | |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | D | 0.00 | 370,400 | 0 | 0 | |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | D | 12.79 | 100,000 | 1,279,000 | 0 | |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | D | 12.79 | 200,000 | 2,558,000 | 0 | |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | D | 0.00 | 50,000 | 0 | 0 | |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | D | 0.00 | 100,000 | 0 | 0 | |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Sell | D | 18.00 | 1,173 | 21,114 | 0 | 1.2 K to 0 (-100.00 %) |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Grant | A | 8.36 | 1,173 | 9,806 | 1,173 | 0 to 1.2 K |
| Jul 02 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Sell | D | 18.00 | 24,529 | 441,522 | 0 | 24.5 K to 0 (-100.00 %) |
| Feb 26 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | A | 0.00 | 150,000 | 0 | 150,000 | |
| Feb 04 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | A | 12.79 | 200,000 | 2,558,000 | 200,000 | |
| Feb 04 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Payment of Exercise | F | 12.89 | 5,623 | 72,480 | 177,928 | 183.6 K to 177.9 K (-3.06 %) |
| Feb 04 2020 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Grant | A | 0.00 | 50,000 | 0 | 183,551 | 133.6 K to 183.6 K (+37.44 %) |
| Nov 04 2019 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Payment of Exercise | F | 29.84 | 21,549 | 643,022 | 133,551 | 155.1 K to 133.6 K (-13.89 %) |
| Jun 07 2019 | KPTI | Karyopharm Therape ... | Garland J. Scott | Director | Option Exercise | A | 5.43 | 25,000 | 135,750 | 25,000 | |
| Feb 04 2019 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | A | 27.10 | 120,400 | 3,262,840 | 120,400 | |
| Feb 04 2019 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Grant | A | 0.00 | 30,100 | 0 | 155,100 | 125 K to 155.1 K (+24.08 %) |
| Oct 31 2018 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Option Exercise | A | 19.69 | 250,000 | 4,922,500 | 250,000 | |
| Oct 31 2018 | PTLA | PORTOLA PHARMACEUT ... | Garland J. Scott | President and CEO | Grant | A | 0.00 | 125,000 | 0 | 125,000 | 0 to 125 K |
| Jun 20 2018 | KPTI | Karyopharm Therape ... | Garland J. Scott | Director | Option Exercise | A | 18.80 | 17,000 | 319,600 | 17,000 | |
| Jun 16 2017 | KPTI | Karyopharm Therape ... | Garland J. Scott | Director | Option Exercise | A | 9.18 | 17,000 | 156,060 | 17,000 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Option Exercise | D | 28.38 | 35,000 | 993,300 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Option Exercise | D | 21.36 | 100,000 | 2,136,000 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Option Exercise | D | 18.87 | 25,000 | 471,750 | 0 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Option Exercise | A | 18.87 | 16,667 | 314,506 | 25,000 | |
| Sep 02 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Sell | D | 32.00 | 16,042 | 513,344 | 0 | 16 K to 0 (-100.00 %) |
| Sep 02 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Sell | U | 32.00 | 2,470 | 79,040 | 16,042 | 18.5 K to 16 K (-13.34 %) |
| Sep 02 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Grant | A | 0.00 | 4,167 | 0 | 18,512 | 14.3 K to 18.5 K (+29.05 %) |
| Aug 17 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Payment of Exercise | F | 31.89 | 705 | 22,482 | 14,345 | 15.1 K to 14.3 K (-4.68 %) |
| Jun 17 2016 | KPTI | Karyopharm Therape ... | Garland J. Scott | Director | Option Exercise | A | 8.06 | 10,000 | 80,600 | 10,000 | |
| Jun 07 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Option Exercise | A | 18.87 | 8,333 | 157,244 | 8,333 | |
| Jun 07 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Payment of Exercise | F | 19.96 | 783 | 15,629 | 15,050 | 15.8 K to 15.1 K (-4.95 %) |
| Jun 07 2016 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Grant | A | 0.00 | 2,083 | 0 | 15,833 | 13.8 K to 15.8 K (+15.15 %) |
| Nov 10 2015 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Grant | A | 0.00 | 6,250 | 0 | 13,750 | 7.5 K to 13.8 K (+83.33 %) |
| Aug 12 2015 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Option Exercise | A | 28.38 | 35,000 | 993,300 | 35,000 | |
| Aug 12 2015 | RLYP | Relypsa Inc | Garland J. Scott | SVP & Chief Commerc ... | Grant | A | 0.00 | 7,500 | 0 | 7,500 | 0 to 7.5 K |
| May 26 2015 | KPTI | Karyopharm Therape ... | Garland J. Scott | Director | Option Exercise | A | 26.15 | 10,000 | 261,500 | 10,000 | |
| Sep 19 2013 | EXEL | EXELIXIS, INC. | Garland J. Scott | EVP & Chief Commeri ... | Option Exercise | A | 5.51 | 150,000 | 826,500 | 150,000 | |
| Sep 21 2012 | EXEL | EXELIXIS, INC. | Garland J. Scott | EVP & Chief Commeri ... | Option Exercise | A | 5.56 | 123,000 | 683,265 | 123,000 | |
| Oct 24 2011 | EXEL | EXELIXIS, INC. | Garland J. Scott | EVP & Chief Commeri ... | Option Exercise | A | 5.47 | 200,000 | 1,094,000 | 200,000 |
Page: 1